[144] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Stoke Therapeutics filed a Form 144 indicating that a person affiliated with the company intends to sell 13,712 common shares, with an aggregate market value of $185,523.36, on or about 08/13/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing states there are 54,797,418 shares outstanding.

The shares to be sold were acquired from the issuer as equity awards: 9,264 restricted stock units on 03/15/2025 and 4,448 performance stock units on 12/03/2024. The filing reports "Nothing to Report" for securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information, with reference to Rule 10b5-1 language.

Positive

• Regulatory disclosure filed providing broker, share count, aggregate value, and planned sale date
• Acquisition details disclosed: 9,264 RSUs (03/15/2025) and 4,448 PSUs (12/03/2024), improving transparency

Negative

• Insider plans to sell 13,712 shares, which investors may view as insider selling (aggregate value $185,523.36)
• No 10b5-1 plan adoption date shown in the visible filing text, so reliance on a prearranged plan is not clearly documented here

Insights

Securities Analyst

TL;DR: Routine Form 144 filing for a small-scale insider sale; unlikely to move market materially.

The Form 144 discloses a planned sale of 13,712 common shares with aggregate value $185,523.36, executed through Morgan Stanley on NASDAQ. Given the size relative to the stated 54,797,418 outstanding shares and the shares being recently issued as RSUs and PSUs, this appears to be a routine award monetization rather than a large disposition. The filing also shows no reportable sales in the prior three months.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 procedures; filing notes standard representation on material information and references Rule 10b5-1.

The notice identifies the broker and provides acquisition details for the securities (dates and award types), which supports transparency and regulatory compliance. The remarks include the customary attestation that the seller is unaware of undisclosed material adverse information. The filing does not list any prior sales in the last three months and does not show a plan adoption date in the visible text, so it is not possible from this document alone to confirm reliance on a dated 10b5-1 plan.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	13712	185523.36	54797418	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2025	Restricted Stock Units	Issuer			9264	03/15/2025	N/A
Common	12/03/2024	Performance Stock Units	Issuer			4448	12/03/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for STOK disclose?

The filing discloses a proposed sale of 13,712 common shares of Stoke Therapeutics (STOK), aggregate value $185,523.36, with an approximate sale date of 08/13/2025.

How many STOK shares are planned to be sold and what is their value?

The notice lists 13,712 shares to be sold with an aggregate market value of $185,523.36.

When and how were the shares being sold acquired?

The shares were issued by the company as equity awards: 9,264 RSUs on 03/15/2025 and 4,448 PSUs on 12/03/2024.

Which broker will execute the sale for STOK?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services (address shown in filing).

Did the filer report any STOK securities sold in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.